Page 5 - Peter Openshaw News Today

A jailed former postmaster last night thanked the Daily Express and its army of readers for their support as he fights to clear this name.

Britain is suffering another wave of COVID-19, fuelled by the recently identified JN.1 variant, as well as the winter season. The impact of COVID is compounded by the increased circulation of flu and other viruses.

JN.1, the currently dominant and highly transmissible Covid-19 sub-variant, may result in a bigger wave than the previous ones, according to global experts.

JN.1, the currently dominant and highly transmissible Covid-19 sub-variant, may result in a bigger wave than the previous ones, according to global experts.The JN.1 variant, classified as a variant of interest (VOI) by the World Health ...

JN.1, the currently dominant and highly transmissible Covid-19 sub-variant, may result in a bigger wave than the previous ones, according to global experts.The JN.1 variant, classified as a variant of interest (VOI) by the World Health ...

JN.1, the currently dominant and highly transmissible Covid-19 sub-variant, may result in a bigger wave than the previous ones

Professor Peter Openshaw, a virus expert at Imperial College London, is warning of a 'major surge' as the JN.1 variant spreads and described the virus strain as 'devious'

{"desktop":[{"injectionEnabled":false,"componentType":"gpt","targeting":{"index":-1,"hivis":"n"},"referenceNode":"header","hideOnSensitiveArticle":true,"hideOnFirstPageView":true,"relativePos":"after","name":"div-gpt-ad-oop-slot","isOOP":true,"type":"outOfPage"},{"componentType":"gpt",&quo...

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants

An 'immune evasive' Covid variant descended from Pirola named JN.1 could end up setting a new UK record after showing rapid growth over Christmas, a scientist has warned